EP Patent

EP1655283A1 — 11beta-HSD1 Inhibitors

Assigned to Evotec OAI AG · Expires 2006-05-10 · 20y expired

What this patent protects

The invention relates to compounds of formula (I) wherein A, Y, Z 1 , Z 2 , R 1 to R 3 and X 1 to X 4 have the meaning as cited in the description and the claims. For example A is 4'-fluorobiphen-4-yl; Y is -S(O) 2 NH-; R 1 , R 2 are H; X 1 , X 2 , X 4 are CH; X 3 is…

USPTO Abstract

The invention relates to compounds of formula (I) wherein A, Y, Z 1 , Z 2 , R 1 to R 3 and X 1 to X 4 have the meaning as cited in the description and the claims. For example A is 4'-fluorobiphen-4-yl; Y is -S(O) 2 NH-; R 1 , R 2 are H; X 1 , X 2 , X 4 are CH; X 3 is C-F; Z 1 is =O; and Z 2 -R 3 is N(CH 2 CH 3 ) 2 . Said compounds are useful as 11β-HSD1 inhibitors. The invention also relates to the preparation of such compounds as well as the production and use as medicament.

Drugs covered by this patent

Patent Metadata

Patent number
EP1655283A1
Jurisdiction
EP
Classification
—
Expires
2006-05-10
Drug substance claim
No
Drug product claim
No
Assignee
Evotec OAI AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.